Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia

Anouk M. La Rose 1, Venetia Bazioti 1, Joanne A. Hoogerland 1, Arthur F. Svendsen 2, Anouk G. Groenen 1, Martijn van Faassen 3, Martijn G.S. Rutten 1, Niels J. Kloosterhuis 1, Bertien Dethmers-Ausema 2, J. Hendrik Hijlind 3, Gilles Mithieux 4, Fabienne Rajas 4, Folkert Kuipers 1,3, Michaël V. Lukens 3, Oliver Soehnlein 5,6, Maaike H. Oosterveer 2, Marit Westerterp 1,7

ABSTRACT

Objective: Glycogen storage disease type 1a (GSD Ia) is a rare inherited metabolic disorder caused by mutations in the glucose-6-phosphatase (G6PC1) gene. When untreated, GSD Ia leads to severe fasting-induced hypoglycemia. Although current intensive dietary management aims to prevent hypoglycemia, patients still experience hypoglycemic events. Poor glycemic control in GSD Ia is associated with hypertriglyceridemia, hepatocellular adenoma and carcinoma, and also with an increased bleeding tendency of unknown origin.

Methods: To evaluate the effect of glycemic control on leukocyte levels and coagulation in GSD Ia, we employed hepatocyte-specific G6pc1 deficient (L-G6pc−/−) mice under fed or fasted conditions, to match good or poor glycemic control in GSD Ia, respectively.

Results: We found that fasting-induced hypoglycemia in L-G6pc−/− mice decreased blood leukocytes, specifically proinflammatory Ly6Chi monocytes, compared to controls. Refeeding reversed this decrease. The decrease in Ly6Chi monocytes was accompanied by an increase in plasma corticosterone levels and was prevented by the glucocorticoid receptor antagonist mifepristone. Further, fasting-induced hypoglycemia in L-G6pc−/− mice prolonged bleeding time in the tail vein bleeding assay, with reversal by refeeding. This could not be explained by changes in coagulation factors V, VII, or VIII, or von Willebrand factor. While the prothrombin and activated partial thromboplastin time as well as total platelet counts were not affected by fasting-induced hypoglycemia in L-G6pc−/− mice, ADP-induced platelet aggregation was disturbed.

Conclusions: These studies reveal a relationship between fasting-induced hypoglycemia, decreased blood monocytes, and disturbed platelet aggregation in L-G6pc−/− mice. While disturbed platelet aggregation likely accounts for the bleeding phenotype in GSD Ia, elevated plasma corticosterone decreases the levels of proinflammatory monocytes. These studies highlight the necessity of maintaining good glycemic control in GSD Ia.

© 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Keywords Glycogen storage disease type 1a; Hypoglycemia; Corticosterone; Monocytes; Platelets

1. INTRODUCTION

Glycogen storage disease type 1a (GSD Ia) is an inborn error of carbohydrate metabolism with an incidence of 1 in 100,000 births [1]. GSD Ia is caused by mutations in the gene encoding the catalytic subunit of the glucose-6-phosphatase enzyme (G6PC1) [2–4]. G6PC1 is expressed in the liver, kidney, and intestine, and catalyzes the hydrolysis of glucose-6-phosphate (G6P) to glucose [1]. Because of the essential role of G6PC1 in endogenous glucose production, GSD Ia patients present with life-threatening fasting hypoglycemia when untreated [1,5]. To prevent hypoglycemia, patients receive dietary therapy that consists of frequent small doses of the slow release carbohydrate source uncooked cornstarch (UCCS) during the day, and UCCS or continuous gastric drip feeding during the night [6,7]. Despite intensive dietary treatment, short periods of hypoglycemia still occur in GSD Ia, generally referred to as poor glycemic control [6,7]. GSD Ia patients exhibit hyperlipidemia, which is aggravated by poor glycemic control [5,8–10]. In addition, they develop severe
hapatomegaly and nonalcoholic fatty liver disease (NAFLD) as a consequence of excessive glycogen and lipid accumulation [11,12], and hepatocellular adenoma, which may progress to carcinoma [6,7,13,14]. Despite prominent hyperlipidemia, GSD Ia patients exhibit a 10% reduction in carotid intima-media thickness [15], reflecting decreased atherosclerotic lesions in the carotid arteries. Under conditions of poor glycemic control, GSD Ia patients show increased bleeding tendency, which complicates surgical procedures [16–18]. This can be prevented by continuous gastric drip feeding to maintain euglycemia for 24 h before surgery [16–18]. Several pathways have been proposed to decrease atherosclerosis and enhance bleeding in GSD Ia [16,18–20]. The exact mechanisms remain elusive, likely due to the relatively small number of GSD Ia patients included in these studies and the high level of clinical heterogeneity [21]. Hypoglycemia caused by poor glycemic control could contribute to the low incidence of atherosclerosis in GSD Ia. Hypoglycemia may decrease blood monocytes, as suggested by others [23]. Low monocyte numbers may decrease atherosclerosis and monocyte-platelet aggregates, which induce coagulation [24,25]. Hypoglycemia may also affect platelet aggregation directly [18,26]. We investigated the effects of glycemic control in GSD Ia on leukocyte levels along with coagulation and the mechanisms involved. We used a mouse model of GSD Ia with hepatocyte-specific G6pc1 deficiency (L-G6pc−/− mice) that were studied under fed or fasted conditions, to match good or poor glycemic control in GSD Ia, respectively [10].

2. MATERIALS AND METHODS

2.1. Animals

Female B6.G6pc1lox/lox and B6.G6pc1lox/lox.SACTERT2 mice were housed in a light (lights on at 7:00 AM, i.e. Zeitgeber time (ZT) 0, lights off at 7:00 PM, i.e. ZT12) and temperature (21 °C)–controlled facility. Mice had free access to water and a standard chow diet (67% carbohydrates, 23% protein and 10% fat (RMH-B, AB diets, Woerden, The Netherlands)). At 6–12 weeks of age, mice received intraperitoneal tamoxifen injections (T5648; Sigma–Aldrich, St. Louis, MO, USA) (1 mg/day in 95% sunflower oil/5% ethanol) for five consecutive days to generate hepatocyte-specific G6pc1 deficient mice (L-G6pc−/−) and littermate floxed controls (control), as described previously [27]. Female littersmates were randomly assigned to experimental groups and the number of mice used for each experiment is indicated in the figure legends. No inclusion or exclusion criteria were used. Experiments were performed for 6–16 weeks after tamoxifen injections at ZT1 (fed), ZT7 (6 h fast during the inactive period or nonfasted), and in case of fasting, the next morning at ZT1 (refeeding during the inactive and active period). All animal studies were approved by the Institutional Animal Care and Use Committee from the University of Groningen under permit number AVD105002015244 and adhered to guidelines set out in the 2010/63/EU directive.

2.2. Blood glucose levels

Blood glucose levels were measured using an Accu-Chek Performa glucose meter (Roche, Basel, Switzerland) and Accu-Chek Performa testing strips (06454011; Roche, Basel, Switzerland).

2.3. White blood cell and platelet counts

Blood samples were collected by tail bleeding into EDTA-coated tubes. Total white blood cell (WBC) and platelet counts were measured using the Medonic CD620 hematology analyzer (Boule Medical, Spanga, Sweden).

2.4. Flow cytometry

Blood samples were collected by tail bleeding into EDTA-coated tubes and kept on ice. For analysis of blood leukocyte subsets, samples were kept at 4 °C during the whole procedure, unless stated otherwise. Red blood cells (RBCs) were lysed for 5 min (BD Pharm Lyse; BD Bioscience, Franklin Lakes, NJ, USA) and WBCs were centrifuged, washed, and resuspended in HBSS (0.1% BSA and 0.5 mM EDTA). To assess monocytes, monocyte subsets, neutrophil, B-cell and T-cell populations, cells were stained with a cocktail of antibodies: CD45-APC-Cy7, CD115-PE, CD19-PE, Ly6C/G-Cy5.5, Ly6G-APC, CD19-PE, CD3-APC-Cy7, CD4-APC-Cy7, CD8-APC-Cy7, CD16/32-FITC, and CD45-PerCP-Cy5.5. Lymphocytes were stained with CD45-APC-Cy7, CD19-PE, and T-cells identified as CD3-APC-Cy7, CD4-APC-Cy7, and CD8-APC-Cy7. For measurements of monocyte and neutrophil surface marker expression, cells were stained with CD45-APC-Cy7 (557659; BD Biosciences, Franklin Lakes, NJ, USA), CD115-APC (17-1152-82; eBioscience, San Diego, CA, USA), Ly6C/G-PercP-Cy5.5 (561103; BD Biosciences, Franklin Lakes, NJ, USA), TCRδ-PE (109226; Biolegend, San Diego, CA, USA), and CD19-PE (152408; Biolegend, San Diego, CA, USA) 30 min on ice in the dark. Monocytes were identified as CD45hiCD115lo, and further separated into Ly6Cand Ly6Csubsets based on the maker Ly6C. Neutrophils were identified as CD45hiCD115loLy6Ghi. Lymphocytes were identified as CD45hiCD115loLy6CandLy6G, and further separated into B-cells identified as CD19hi, and T-cells identified as TCRδhi. For measurements of monocyte and neutrophil surface marker expression, cells were stained with CD45-APC-Cy7 (557659; BD Biosciences, Franklin Lakes, NJ, USA), CD115-APC (17-1152-82; eBioscience, San Diego, CA, USA) or CD115-PE (135506; Biolegend, San Diego, CA, USA), and Ly6C/G-PercP-Cy5.5 (561103; BD Biosciences, Franklin Lakes, NJ, USA). C–C chemokine receptor 2 (CCR2) -PE (FABS538P; R&D systems, CA).
For analysis of bone marrow leukocyte and progenitor cell populations, the femur and tibia were collected, bone marrow (BM) was harvested and mashed through a 40 μm strainer. RBCs were lysed for 2 min on ice. WBCs were centrifuged, washed, and resuspended in HBSS (0.1% BSA and 0.5 mM EDTA). Total WBC counts were measured using the Medonic CD620 hematology analyzer (Boule Medical, Sanga, Sweden). Leukocyte subsets in BM were assessed by flow cytometry using the staining described for blood WBCs. For analysis of progenitor populations, cells were stained with a cocktail of antibodies (all from Biolegend, San Diego, CA, USA, unless stated otherwise): Sca1-BV421 (108127), ckit-APC (105812), CD127-PE (135010), CD16/32-PE-Cy7 (101318), CD34- FITC (555373; BD biosciences, Franklin Lakes, NJ, USA), B220-A700 (103231), CD11b-A700 (101222), CD3-A700 (100216), Ly6C/G-A700 (108422), and Ter119-A700 (116220) for 30 min on ice in the dark. Hematopoietic stem and progenitor cells were identified as CD127⁺ lineage (Lin⁻), Sca1⁻, and ckit⁻ (LSK). Hematopoietic progenitors were identified as Lin⁻, CD127⁺, Sca-1⁺, ckit⁻ cells, and further separated into CD34⁺, CD16/32⁺, common myeloid progenitors (CMP), and CD34⁻CD16/32⁻ granulocyte/monocyte progenitors (GMP).

For analysis of hepatic monocytes and neutrophils, livers were collected, digested using collagenase (1.5 mg/ml in PBS) (C5138; Sigma—Aldrich, St. Louis, MO, USA) for 45 min at 37 °C and washed through a 40 μm strainer. Up to 50 ml PBS was added and samples were centrifuged at 70 x g with brake settings off for 5 min. The upper layer containing the hepatic leukocytes was centrifuged at 400 x g for 10 min and RBCs were lysed for 2 min on ice. Samples were centrifuged, washed, and resuspended in HBSS (0.1% BSA and 0.5 mM EDTA). CD45⁺ cells were isolated from liver homogenates using CD45-coated magnetic beads (130-052-301; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s instructions. Total WBC counts were measured using the Medonic CD620 hematology analyzer (Boule Medical, Sanga, Sweden). To assess hepatic monocytes and neutrophils, CD45⁺ cells were stained with CD45-APC-Cy7 (557659; BD Biosciences, Franklin Lakes, NJ, USA), CD11b-PB (552093; BD Biosciences, Franklin Lakes, NJ, USA), and Ly6C/G-PercP-Cy5.5 (561103; BD Biosciences, Franklin Lakes, NJ, USA) as described for blood WBCs. Monocytes were identified as CD45⁺CD11b⁺Ly6C⁻/SSC⁺ and neutrophils as CD45⁺CD11b⁺Ly6G⁻/SSC⁺. All samples were analyzed on an LSRII (BD Biosciences, Franklin Lakes, NJ, USA), running FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). Data were analyzed using FlowJo software (FlowJo, Ashland, OR, USA). CCR2 expression was analyzed as mean fluorescence intensity (MFI).

2.5. ELISAs
Blood samples were collected. Plasma was separated by centrifugation, and monocyte chemotactrant protein-1 (MCP-1), macrophage-colony stimulating factor (M-CSF), and granulocyte-colony stimulating factor (G-CSF) were measured using ELISA kits (MJ900, MMC00, and MCS80, respectively; R&D systems, Minneapolis, MN, USA) according to the manufacturer’s instructions.

2.6. Mifepristone treatment
Six weeks after tamoxifen injections, mice received an intraperitoneal injection with the glucocorticoid receptor antagonist mifepristone (M8046; Sigma—Aldrich, St. Louis, MO, USA) (25 mg/kg in 90% sunflower oil/10% ethanol) or vehicle at the start of the 6 h fasting period.

2.7. Plasma triglycerides and lipoprotein analysis
Blood samples were collected. Plasma was separated by centrifugation and plasma triglyceride (TG) and free fatty acid (FFA) levels were measured using enzymatic kits (157.109.910.917 and 157.819.910.935, respectively; Diasys Diagnostic Systems, Holzheim, Germany) with Precimat Glycerol or FFA standard FS (10,166,588; Roche, Mannheim, Germany and 157.809.910.965; Diasys Diagnostic Systems, respectively) for the calibration curve. Lipoprotein TG distribution was measured by fast performance liquid chromatography (FPLC) using a system containing a PU-4180 pump with a linear degasser and UV-4075 UV/VIS detectors (Jasco, Tokyo, Japan). Pooled plasma samples (n = 8—12) were injected onto a Superox 6 Increase 10/300 GL column (GE Healthcare, Hoelvaken, The Netherlands) and eluted at a constant flow rate of 0.31 ml/min in PBS (pH 7.4). Triglycerides were measured in line by the addition of TG reagent (157.109.910.917; Diasys, Holzheim, Germany) at a constant flow rate of 0.1 ml/min using an additional PU-4080i infusion pump (Jasco, Tokyo, Japan). Data acquisition and analysis were performed using ChromNav software (version 1.0; Jasco, Tokyo, Japan).

2.8. Flow cytometry of platelet-leukocyte aggregates
For the analysis of platelet-leukocyte aggregates, blood was collected by retro-orbital bleeding into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nürmbrecht, Germany) and kept at RT. Samples were kept at 4 °C for all subsequent steps. RBCs were lysed for 5 min (BD Pharm Lyse, BD Bioscience, Franklin Lakes, NJ, USA), samples were centrifuged, washed, and resuspended in HBSS (0.1% BSA and 0.5 mM EDTA). To assess platelet-monocyte and platelet-neutrophil aggregation, samples were incubated with a cocktail of antibodies: CD45-APC-Cy7 (557659; BD Biosciences, Franklin Lakes, NJ, USA), CD115-PE (135506; Biolegend, San Diego, CA, USA), Ly6C/G-PercP-Cy5.5 (571103; BD Biosciences, Franklin Lakes, NJ, USA), CD41- FITC (133904; Biolegend, San Diego, CA, USA) for 30 min on ice in the dark. Platelet-monocyte aggregates were identified as CD45⁺CD115⁺CD41⁺, and were further separated into platelet-Ly6C⁺ monocyte aggregates, defined as CD45⁺CD115⁺Ly6C⁺CD41⁺, and platelet-Ly6G⁺ monocyte aggregates, defined as CD45⁺CD115⁺Ly6G⁺CD41⁺. Platelet-neutrophil aggregates were identified as CD45⁺CD115⁺Ly6G⁺CD41⁺. All samples were analyzed on an LSRII (BD Biosciences, Franklin Lakes, NJ, USA), running FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA). The data were analyzed using FlowJo software (FlowJo, Ashland, OR, USA).

2.9. Plasma corticosterone, epinephrine, and norepinephrine
Blood was collected by retro-orbital bleeding into EDTA-coated tubes (450532; Greiner Bio-One, Kremsmünster, Austria) and kept on ice. Plasma was separated by centrifugation and 5 mg reduced glutathione (G4251; Sigma—Aldrich, St. Louis, MO, USA) was added per mL of plasma after centrifugation to prevent degradation of epinephrine and norepinephrine. Plasma was snap-frozen and stored at −80 °C until further use. Corticosterone, epinephrine, and norepinephrine were measured by online solid phase extraction (SPE) in combination with isotope dilution liquid chromatography tandem mass spectrometry (LC-MS/MS). Corticosterone measurement was performed essentially as described by Hawley et al. [28], using corticosterone-D4 as a stable isotope-labeled internal standard on an online SPE manager in combination with a XEVO TQ mass spectrometer (Waters, Milford, MA, USA). Epinephrine and norepinephrine
were analyzed as described by Van Faassen et al. [29], using epinephrine-D3 and norepinephrine-D6 as stable isotope-labeled internal standard on a Symbiosis Pharma online SPE system (Spark Holland, Emmen, The Netherlands) in combination with a Xevo TQ mass spectrometer (Waters, Milford, MA, USA).

2.10. Adrenal gland mass
Twelve weeks after tamoxifen injections, mice were sacrificed by cardiac puncture in the fed or fasted condition. Adrenal glands were collected, cleaned of surrounding fat, and weighed.

2.11. Tail vein bleeding assay
The tail vein bleeding assay was performed as described previously [30]. Briefly, mice were anesthetized with isoflurane. A 10 mm segment of the distal tip of the tail was removed using a scalpel. The tail was immediately immersed in a 50 ml tube containing 50 ml phosphate-buffered saline (PBS) prewarmed to 37 °C. Time until the bleeding ceased was recorded with a maximum bleeding time of 300 s. Volume of blood loss during the bleeding assay was quantified by measuring absorbance at 550 nm using a spectrophotometer (Genesys 10S UV-Vis; Thermofisher Scientific, Waltham, MA, USA).

2.12. Prothrombin time, activated partial prothrombin time, and plasma coagulation factors
Blood was collected by cardiac puncture into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nümbrecht, Germany). Samples were immediately centrifuged at RT to collect plasma. Plasma was stored at −80 °C until further use. Prothrombin time (PT) and activated partial thrombin time (aPTT) were assessed on an automated coagulation analyzer (CS-2100i) with reagents (PT-Innovin for PT and ActinFS for aPTT) and protocols from the manufacturer (Siemens, Marburg, Germany). Levels of factor V (FV), VII (FVII), and FVIII (FVIII) were determined on an automated coagulation analyzer (CS2100i) based on the one-stage clotting assay with factor-deficient plasma (Siemens, Marburg, Germany). Testing was performed in accordance with the protocols from the manufacturer (Siemens). Levels are denoted as percentages of standard human plasma (Siemens, Marburg, Germany).

2.13. Von Willebrand ristocetin cofactor
Blood was collected by cardiac puncture into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nümbrecht, Germany). Samples were immediately centrifuged at RT to collect plasma. Plasma was stored at −80 °C until use. Von Willebrand ristocetin cofactor (vWF RCF) levels were determined on a CS2100i coagulation analyzer with the Innocova vWF activity kit (Siemens, Marburg, Germany) in accordance with the protocol from the manufacturer with all equipment and reagents from Siemens (Marburg, Germany).

2.14. Platelet aggregation
To assess platelet aggregation, blood was drawn by cardiac puncture and collected into tubes containing 3.2% sodium citrate (9:1 v/v) (41.1506.002; Sarstedt, Nümbrecht, Germany). Samples were kept at RT during the whole procedure. Samples were centrifuged at 110 x g and platelet-rich plasma (PRP) was collected. PRP was diluted to a final concentration of 200 x 10^9 platelets per mL using platelet-poor plasma (PPP) from the same mouse. Platelet aggregation in response to 10 μM ADP was measured using light transmission aggregometry (Chrono-log Model 700; Chrono-log Corporation, PA, USA) at 37 °C, stirring at 1200 rpm. Light transmission was recorded for 10 min using Aggro-Link 8 software.

2.15. Statistical analysis
All data are presented as mean ± SEM. The unpaired t-test was used to compare two datasets. To compare ≥3 groups, a one-way ANOVA with Bonferroni post hoc test was performed. Group size and statistical tests are reported in the figure legends. The criterion for significance was set at P < 0.05. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software; San Diego, CA, USA).

3. RESULTS
3.1. Fasting decreases blood leukocytes in L-G6pc−/− mice
We first confirmed that similar to previous studies [27,31], hepatocyte-specific G6pc1 deficiency induces hypoglycemia after a fasting period of 6 h. For this purpose, we measured blood glucose levels at Zeitgeber time (ZT) 1 (fed), ZT7 (6 h fast during the inactive period or nonfasted), and the next morning at ZT1 (refeeding during the inactive and active period). In accordance with previous studies [27], L-G6pc−/− mice exhibited hypoglycemia (blood glucose < 4.0 mM) after a 6 h fast, with average blood glucose levels of ~3.6 mM (Figure 1A). Refeeding restored blood glucose levels to ~7.9 mM (refeeding; ZT1) (Figure 1A). L-G6pc−/− mice maintained euglycemia when they did not fast (Figure 1B) probably because of the Chow diet given to Gsd la patients that resembles the dietary therapy. Gsd la patients are on a dietary therapy of uncooked cornstarch that has a glycemic index of 48 [32], and as a consequence induces the slow release of glucose, preventing hypoglycemia in these patients [7]. Chow diet contains 67% carbohydrates with a glycemic index of 54 and 28 (specified in the methods section), which explains why L-G6pc−/− mice maintain euglycemia when not fasted. We observed the decrease in blood glucose levels in L-G6pc−/− mice upon a 6 h fast at all time points measured throughout the study (Figure S1A and B).

Previous studies have revealed that prolonged fasting (20 h) leads to hypoglycemia, which decreases blood monocyte levels [23]. We thus assessed whether hepatocyte-specific G6pc1 deficiency affected blood leukocytes in the fasted and nonfasted condition. Control mice exhibited an increase in total CD45+ blood leukocyte levels after fasting, because of circadian rhythmicity [33], whereas L-G6pc−/− mice did not (Figure 1C). Refeeding restored blood leukocyte levels in L-G6pc−/− mice (ZT1; refeeding) (Figure 1C). We observed no differences in blood leukocytes when L-G6pc−/− mice were not fasted and they remained euglycemic (Figure 1D). Further analysis of leukocyte subsets in fasted animals denoted that hepatocyte-specific G6pc1 deficiency decreased total monocytes by ~50%, mainly reflected by decreases in proinflammatory Ly6Chi and to a lesser extent Ly6Clo monocytes (Figure 1E). Though our data suggest that fasting-induced changes could account for the decrease in blood Ly6Chi monocytes in L-G6pc−/− mice during fasting, blood Ly6Clo monocyte levels represented a strong correlation with blood glucose levels in L-G6pc−/− mice, but not in control mice upon a 6 h fast (Fig. S2; Pearson correlation coefficient r = 0.65; p = 0.009), suggesting a major contribution of hypoglycemia to the decreased blood monocytes upon fasting. Fasting also increased plasma VLDL-TG and VLDL-cholesterol in L-G6pc−/− mice [10]. However, elevated VLDL-cholesterol increases Ly6Chi monocytes in mice [34]. We found that fasting did not affect plasma FFAs in L-G6pc−/− mice, although plasma FFAs were elevated in the fed and fasted state, compared to controls (Fig. S3). Hence it is unlikely that lipids have contributed to the decreased blood Ly6Chi monocytes in fasted L-G6pc−/− mice. Though our data suggest that hypoglycemia is a key factor in decreasing blood monocytes, we cannot...
Figure 1: Fasting decreases blood monocytes and neutrophils in L-G6pc−/− mice. Hepatocyte-specific G6pc deficiency was induced by tamoxifen injections. After 6–16 weeks of tamoxifen injections, blood glucose and leukocyte levels were assessed at Zeitgeber time (ZT) 1 (fed), ZT7 (6 h fast during the inactive period or non fasted), and, in case of fasting, the next morning at ZT1 (refeeding during the inactive and active period). For each experiment, the same mouse was measured in the fed (ZT1) and fasted (ZT7) or non fasted (ZT7) condition, and in case of fasting, in the refed condition (ZT1, the next morning). (A–B) Blood glucose levels. (C–D) Total CD45+ leukocyte levels. (E–H) Representative flow cytometry plots of monocyte and neutrophils as a percentage of CD45+ leukocytes. Monocyte subsets are given in the fed (E–F) and fasted (G–H) condition. Neu denotes neutrophils. (I–P) Quantification of total monocytes, monocyte subsets, and neutrophils in the fed, fasted or non fasted, and refed condition. (n = 12–16). Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by t-test. Experiments have been repeated 6 times with similar results.
exclude that hormonal changes in fasted L-G6pc−/− mice [35] may have contributed to the decrease in monocytes. Administration of glucose by gavage during the fasting period, as carried out in wild-type mice in experiments by Jordan et al. [23], led to an even further aggravated hypoglycemia in L-G6pc−/− mice (results not shown), similar to rapid changes in blood glucose levels and rebound hypoglycemia that have been observed upon glucose administration in GSD Ia patients [7]. Therefore, we could not assess the effect of glucose on leukocyte changes in L-G6pc−/− mice directly. Neutrophils exhibited a similar response to monocytes in fasted and refed L-G6pc−/− mice, although fasting decreased neutrophils by only ~26% (Figure S1G,H,O,P). T- and B-cells were similarly affected (Figure S4A–F), with effects on B-cells being most pronounced. Collectively, hepatocyte-specific G6pc1 deficiency decreased circulating leukocytes upon a 6-h fast, which was restored by refeeding. All leukocyte populations were affected, and we observed major decreases in monocytes, particularly the Ly6Chi population, along with B-cells.

3.2. Fasting increases plasma corticosterone levels in L-G6pc−/− mice

We then sought to elucidate the mechanism causing the decrease in Ly6C+ monocytes in L-G6pc−/− mice upon fasting. MCP-1 enhances the recruitment of Ly6C+ monocytes from bone marrow by interacting with CCR2 on these cells [36–38]. A previous study has revealed that hypoglycemia decreases blood monocytes as a consequence of a reduction in plasma MCP-1 levels [23]. MCP-1 levels in the plasma of L-G6pc−/− mice were not affected compared to controls after a 6 h fast (Figure S5A). M-CSF was also not affected (Figure S5B). We observed a similar increase in plasma G-CSF levels (Figure S5C), which cannot explain the fasting-induced reduction in blood neutrophils in L-G6pc−/− mice. We then studied surface markers on monocytes and neutrophils. CCR2, CD11b, and VLA4 expression on Ly6C+ monocytes were not affected in L-G6pc−/− mice compared to controls after a 6 h fast (Figure S5D), as were CXCR4, CD62L, CXCR2, and CD11b on neutrophils (Figure S5E). This means hepatocyte-specific G6pc1 deficiency does not affect surface markers on monocytes and neutrophils upon fasting, suggesting no difference in the functionality of these cells. We then assessed where myeloid cells would accumulate during fasting-induced hypoglycemia in hepatocyte-specific G6pc1 deficiency. We observed an increase in monocytes in bone marrow in L-G6pc−/− mice upon fasting (Figure 2A). Although most bone marrow monocytes are Ly6C+, the Ly6C+ population was increased, perhaps because monocytes lose their Ly6C expression upon retention in the bone marrow. Stem and progenitor cells including LSK cells, CMPs, and GMPS that give rise to myeloid cells were not affected in the bone marrow of fasted L-G6pc−/− mice (Figure 2B), or in the spleen or liver (results not given). Livers from L-G6pc−/− mice exhibited increased neutrophils (Figure 2C), in accordance with a previous study where this was attributed to increased hepatic expression of the neutrophil chemoattractant keratinocyte-derived chemokine (KC) that stimulates neutrophil infiltration [39,40]. The decrease in blood monocytes upon fasting in L-G6pc−/− mice may be caused by their accumulation in the bone marrow and the decrease in neutrophils because of their accumulation in the liver.

We further investigated the mechanism underlying the decrease in blood Ly6C+ monocytes and their accumulation in bone marrow upon fasting-induced hypoglycemia in hepatocyte-specific G6pc1 deficiency. Hypoglycemia evokes a stress response that leads to increased plasma corticosterone levels in mice [41]. Corticosterone impairs the recruitment of monocytes from the bone marrow [42,43]. Bone marrow monocytes are mostly from the Ly6C+ subset [38]. We thus hypothesized that the decrease in Ly6C+ monocytes was caused by increased corticosterone levels as a result of hypoglycemia in fasted L-G6pc−/− mice. We measured levels of corticosterone and other stress hormones. While fasting increased plasma corticosterone levels in both genotypes, L-G6pc−/− mice presented a 2-fold higher plasma corticosterone level than controls after fasting (Figure 3A). Adrenal gland mass was not affected after a 6 h fast, likely because the increase in plasma corticosterone was an acute effect (Figure S6). Corticosterone increases the activity of the enzyme phenylethanolamine N-methyltransferase (PNMT), which mediates the conversion of norepinephrine into epinephrine [44]. In line with an increase in corticosterone levels, epinephrine levels were also increased by 2-fold upon fasting in L-G6pc−/− mice compared to controls (Figure 3B), whereas norepinephrine levels were unaffected (Figure 3C). Corticosterone and epinephrine have counter-regulatory effects on blood monocytes [42,43,45]. We observed a decrease in blood monocytes upon fasting and therefore hypothesized that the effect of corticosterone on blood monocytes is predominant, and investigated this further.

3.3. Inhibition of corticosterone signaling prevents the fasting-induced decrease in blood Ly6C+ monocytes in L-G6pc−/− mice

We then assessed whether the reduction in Ly6C+ monocytes in fasted L-G6pc−/− mice was dependent on the increase in plasma corticosterone levels. We injected mice with the glucocorticoid receptor antagonist mifepristone or vehicle at the start of the fasting period. Strikingly, mifepristone completely prevented the fasting-induced decrease in total CD45+ leukocytes in L-G6pc−/− mice (Figure 4A). Mifepristone also prevented the fasting-induced decrease in Ly6C+ monocytes in L-G6pc−/− mice, whereas effects on other leukocyte populations did not reach statistical significance (Figures 4B and S7). These data confirm our hypothesis that the decrease in Ly6C+ monocytes in fasted L-G6pc−/− mice is due to an exaggerated stress response caused by elevated plasma corticosterone.

A recent study has revealed that hypoglycemia in hepatocyte-specific G6pc1 deficient mice impairs very-low-density lipoprotein (VLDL) catabolism, which was suggested to be caused by decreased lipoprotein lipase (LPL) activity [10]. As a result, plasma triglyceride levels were elevated [10]. Corticosterone may inhibit LPL activity [46,47]. We thus assessed whether the increase in plasma VLDL-triglycerides (VLDL-TG) in fasted L-G6pc−/− mice was dependent on plasma corticosterone levels. Mifepristone prevented the increase in plasma VLDL-TG upon fasting in L-G6pc−/− mice (Figure S8A and B), suggesting that elevated corticosterone levels contribute to fasting-induced hypertriglyceridemia in GSD Ia.

3.4. Fasting increases bleeding time in L-G6pc−/− mice

The increased bleeding tendency in GSD Ia has been attributed to the decrease in von Willebrand factor (vWF) [19], disturbed platelet aggregation [16,18], and increased blood pressure [48]. Myeloid cells such as monocytes and neutrophils form leukocyte-platelet aggregates that contribute to coagulation [24]. Hence, a fasting-induced decrease in myeloid cells may reduce the formation of leukocyte-platelet aggregates, impair blood coagulation, and increase bleeding time. To test this hypothesis, we first assessed bleeding time in L-G6pc−/− mice in the fed, fasted, nonfasted, and refed condition using the tail vein bleeding assay. Similar to observations in GSD Ia patients with poor glycemic control, fasting increased bleeding time in L-G6pc−/− mice (Figure 5A). Further confirming these data, L-G6pc−/− mice exhibited an increase in blood loss per minute upon fasting compared to controls (Figure 5B). The increased bleeding time and blood volume loss per minute were restored upon refeeding. Bleeding time and blood volume...
loss per minute were not affected in the fed and nonfasted states. Collectively, these data show that fasting prolongs bleeding time in L-G6pc/C0/C0 mice. We then investigated whether prolonged bleeding time upon fasting was caused by a decrease in monocyte-aggregates and neutrophil-aggregates because of a fasting-induced reduction in myeloid cells in L-G6pc/C0/C0 mice. The percentage of monocytes and neutrophils that formed aggregates with platelets (CD41+CD41+) was not affected by hepatocyte-specific G6pc1 deficiency (Figure S9A and B). This indicates that the capacity of monocytes and neutrophils to form aggregates with platelets did not change under fasting conditions. Nonetheless, the absolute decrease in these cell populations could contribute to less myeloid cell-platelet aggregates and increased bleeding during fasting in hepatocyte-specific G6pc1 deficiency.

3.5. Fasting does not decrease coagulation factors in L-G6pc−/− mice
We next investigated other mechanisms accounting for the fasting-induced increase in the bleeding time of L-G6pc−/− mice. Since coagulation factors are mainly produced by the liver [49], where G6pc1 is highly expressed [50], we first assessed whether coagulation factors secreted by the liver and downstream pathways were affected by hepatocyte-specific G6pc1 deficiency. Prothrombin (PT) time, reflecting the intrinsic coagulation pathway that is dependent on factor VII and the common pathway consisting of factors X, II (thrombin), and I (fibrinogen), was not affected (Figure 6A). Activated partial thromboplastin time (aPTT), reflecting the extrinsic coagulation pathway that depends on factors XI, XII, VIII, and IX, was also not affected (Figure 6B). Plasma levels of coagulation factors V (FV) and
VIII (FVIII) were increased in L-G6pc/C0/C0 mice in the fed and fasted condition, while factor VII (FVII) was not affected (Figure 6C). The increases in FV and FVIII would increase coagulation, and hence, these increases are unlikely to explain the bleeding phenotype of L-G6pc/C0/C0 mice. It has been described that GSD Ia patients exhibited decreased vWF levels [19]. On the contrary, we found that L-G6pc/C0/C0 mice exhibited increased vWF levels upon fasting (Figure 6F). The increase in plasma vWF and FVIII could be the consequence of the fasting-induced increase in plasma corticosterone [51–53]. Similar to FV and FVIII, vWF would increase coagulation. Therefore, these increases cannot explain the prolonged bleeding phenotype in fasted L-G6pc/C0/C0 mice. Hence, the bleeding phenotype in L-G6pc/C0/C0 mice upon fasting is not due to decreases in vWF, FVIII, or coagulation factors produced by the liver.

### 3.6. Fasting disturbs platelet aggregation in L-G6pc/C0/C0 mice

Even though the number of patients was limited (between 2 and 7 per study), it has been reported that GSD Ia patients exhibit disturbed platelet aggregation [16–18]. This could account for the prolonged bleeding time in GSD Ia. We thus assessed whether fasting affected platelet aggregation in L-G6pc/C0/C0 mice. Blood platelet counts were not different between genotypes in both the fed and fasted condition (Figure 7A), but studies on platelet function did reveal distinct differences. Initially, ADP-induced stimulation of platelet-rich plasma from both controls and L-G6pc/C0/C0 mice led to aggregation in both the fed and fasted condition (Figure 7B). Strikingly, after maximum aggregation had been reached, platelets isolated from fasted mice, but not from non-fasted L-G6pc/C0/C0 mice, showed ~50% platelet disaggregation (Figure 7B,C). Hence, hepatocyte-specific G6pc1 deficiency disturbs platelet aggregation after fasting. Among all mechanisms that we have explored, it is most likely that disturbed platelet aggregation accounts for the prolonged bleeding time in L-G6pc/C0/C0 mice. We anticipate that this is also the main mechanism accounting for the bleeding tendency observed in hypoglycemic GSD Ia patients.

### 4. DISCUSSION

Our findings reveal that hepatocyte-specific G6pc1 deficiency in mice increases plasma corticosterone levels, decreases blood leukocytes, and disturbs platelet aggregation upon fasting. These results are most likely the consequence of fasting-induced hypoglycemia. The fasting-induced decrease in leukocytes in hepatocyte-specific G6pc1 deficiency was mainly reflected by a decrease in Ly6Chi monocytes and was prevented by the glucocorticoid receptor antagonist mifepristone.
Figure 5: Fasting increases bleeding time in L-G6pc−/− mice. Hepatocyte-specific G6pc1 deficiency was induced by tamoxifen injections. After 6–12 weeks of tamoxifen injections, bleeding time was assessed in the fed, fasted, non fasted, and refed condition. (A) Bleeding time was recorded during a tail vein bleeding assay. (B) Blood volume loss per minute was quantified by measuring absorbance at 550 nm using a spectrophotometer. Each data point represents an individual mouse. (n = 6–8). Data are shown as mean ± SEM. **p < 0.01, ***p < 0.001, by t-test. Experiments have been repeated 4 times with similar results.

Figure 6: Effects of hepatocyte-specific G6pc1 deficiency on plasma levels of coagulation factors. Hepatocyte-specific G6pc1 deficiency was induced by tamoxifen injections. At 16 weeks after tamoxifen injections, (A) prothrombin time (PT) and (B) activated partial thromboplastin time (APTT) were assessed in the fed and fasted condition. (C) Plasma levels of coagulation factor V (FV), (D) factor VII (FVII), (E) factor VIII (FVIII), and (F) von Willebrand factor activity (vWF RCF) were measured in the fed and fasted condition. For each experimental condition (fed and 6 h fast), individual mice were used. (n = 6–8). Data are shown as mean ± SEM. **p < 0.01, ***p < 0.001, by t-test.
Furthermore, we found that hepatocyte-specific G6pc1 deficiency prolonged bleeding time upon fasting due to disturbed platelet aggregation. Previous studies have recognized a relationship between hyperglycemia and monocytosis [54], and our data also indicate a similar relationship under conditions of fasting-induced hypoglycemia in hepatocyte-specific G6pc1 deficiency, reflected by decrease in blood monocyte levels and disturbed platelet aggregation.

A relationship between glucose levels and blood monocytes in the setting of transient intermittent hyperglycemia independent of diabetes, and prolonged fasting has been shown previously [54]. Four injections of glucose over a period of 6 h increase blood monocyte levels, particularly the Ly6Chi population in wild-type mice [54], and a fasting period of 20 h decreases blood monocytes in wild-type mice, with reversal by glucose administration [23]. Similarly, a 19 h fasting period in humans decreases plasma glucose levels and blood monocytes [23]. Several studies thus indicate a positive relationship between blood monocytes and plasma glucose levels [23,54], sharing similarities with our observations in a mouse model of hepatic GSD Ia. While transient intermittent hyperglycemia increases blood monocytes because of elevated S100A8/A9 secretion by neutrophils as a consequence of glucose transporter (GLUT)-1 mediated glucose uptake [54], the decrease in blood monocytes upon hypoglycemia during

Figure 7: Fasting induces platelet disaggregation in L-G6pc−/− mice. Hepatocyte-specific G6pc1 deficiency was induced by tamoxifen injections. After 6–16 weeks of tamoxifen injections, blood platelet counts and platelet aggregation were assessed in the fed and fasted condition. (A) Blood platelet counts were measured in the fed condition and again in the same mouse after a 6 h fast. (n = 12–16). (B–C) Platelet aggregation in response to 10 μM ADP in platelet-rich plasma was measured using light transmission aggregometry. Representative platelet aggregation responses are shown (B) and quantified (C). Platelet disaggregation is denoted as the percentage of maximum aggregation response (C). For each experimental condition (fed and 6 h fast), individual mice were used. (n = 9–11). Data are shown as mean ± SEM. **p < 0.01, by t-test.
prolonged fasting is considered to be secondary to a decrease in MCP-1 [23]. MCP-1 interacts with its receptor CCR2 on bone marrow monocytes to promote their egress from the bone marrow into blood [36–38]. We did not detect differences in plasma MCP-1 upon fasting-induced hypoglycemia in hepatocyte-specific G6pc1 deficiency, but we did observe an increase in plasma corticosterone and epinephrine. Corticosterone decreases blood monocytes, but epinephrine has the opposite effect [45]. In diabetes, injections of insulin increase epinephrine levels [55] and blood monocytes [45], and presumably as a consequence thereof, patients with type 2 diabetes exhibit high levels of blood monocytes [22], although hyperglycemia also contributes to this effect [22]. Nonetheless, the question remains as to why monocytes were not increased as a consequence of the increased epinephrine in mice with hepatocyte-specific G6pc1 deficiency, similar to effects of insulin injections in patients with diabetes. We assume that this relates to diabetic patients having impaired adrenocorticotrophic hormone responses to hypoglycemia, leading to the suppression of cortisol production by the adrenal gland [56]. As such, cortisol levels are not upregulated during hypoglycemia as a consequence of insulin injections [56], whereas epinephrine levels do increase, leading to elevated blood monocyte levels. Our studies showed that fasting-induced hypoglycemia in hepatocyte-specific G6pc1 deficiency increases plasma levels of both corticosterone and epinephrine, and the decrease in blood monocytes suggests that the effect of corticosterone is predominant. Indeed, we found that the corticosterone receptor antagonist mifepristone reversed the fasting-induced decrease in Ly6C<sup>hi</sup> monocytes in L-G6pc<sup>−/−</sup> mice. We mainly observed differences in the Ly6C<sup>hi</sup> monocyte subset, presumably because corticosterone impairs the egress of monocytes from the bone marrow [42,43,57], and most bone marrow monocytes are Ly6C<sup>hi</sup> [38]. This is consistent with previous studies in rats demonstrating that acute stress or administration of corticosterone decreases blood monocytes within 2 h [42,58]. B-cells were also reduced by fasting in L-G6pc<sup>−/−</sup> mice. Previous studies have shown that blood B-cell levels are controlled by corticosterone, at least when corticosterone levels are elevated for a long period (72 h) [59]. Mifepristone tended to reverse the decrease in B-cells in L-G6pc<sup>−/−</sup> mice, although this did not reach statistical significance. Previous studies have also revealed that myocardial infarction (MI) leads to activation of the sympathetic nervous system, increasing norepinephrine production which acts on β<sub>2</sub>-adrenoceptors in bone marrow and promotes stem cell mobilization within 48 h of MI [60]. We did not observe any differences in norepinephrine levels or on hematopoietic stem and progenitor cells in the bone marrow, indicating that this mechanism did not play a role in L-G6pc<sup>−/−</sup> mice. GSD Ia patients display elevated levels of cortisol, the human homolog of corticosterone [61]. This was observed in the fed state, under conditions of good glycemic control. This effect was attributed to the production of NADPH in hepatocytes resulting from G6P accumulation. NADPH is a co-factor required for 11β-HSD1 reductase activity [62], resulting in the conversion of inactive glucocorticoids (cortisone in humans and 11-dehydrocortisone in mice) into active glucocorticoids (cortisol and corticosterone in humans and mice, respectively) [63]. GSD Ia patients exhibit increased conversion of administered cortisone into cortisol after overnight dexamethasone suppression [62], consistent with increased 11β-HSD1 reductase activity and elevated plasma cortisol levels [61]. Although L-G6pc<sup>−/−</sup> mice do accumulate G6P in the liver, 11β-HSD1 reductase activity was not affected [62]. This is likely the consequence of 11β-HSD1 reductase activity being 20 times higher in mice than in humans [62,64], and may explain why plasma corticosterone is not elevated in L-G6pc<sup>−/−</sup> mice in the fed state.

The increase in plasma cortisol in the fed state does not exclude that GSD Ia patients might exhibit high cortisol levels upon fasting-induced hypoglycemia, similar to mice with hepatocyte-specific G6pc1 deficiency. Hypoglycemia in GSD Ia patients correlates with hyperlipidemia, in particular, increased VLDL-TGs [7,10,65,66]. Cortisol increases VLDL-TG plasma levels [67,68]. We found that the glucocorticoid receptor antagonist mifepristone suppressed the fasting-induced increase in plasma VLDL-TG in L-G6pc<sup>−/−</sup> mice, consistent with a role for this antagonist in promoting VLDL-TG clearance, as suggested [69]. These data indicate that increased plasma cortisol caused by poor glycemic control contributes to high plasma VLDL-TG levels in GSD Ia patients [46,47].

Despite elevated VLDL-TG levels, a study in 9 GSD Ia patients has revealed that carotid intima-media thickness was not increased in GSD Ia patients compared to controls [15]. This effect can be explained as VLDL particles being too large to enter the vessel wall, similar to a setting of Apolipoprotein C3 overexpression in mice [70]. Nonetheless, our data reveal that in a setting of poor glycemic control, levels of blood proinflammatory Ly6C<sup>hi</sup> monocytes are decreased. Ly6C<sup>hi</sup> monocytes infiltrate into atherosclerotic lesions [71]. Monocytosis enhances atherosclerosis, as revealed by studies in animal models [71] and humans [72]. The outcome of our studies suggests that conditions of poor glycemic control in GSD Ia patients may reduce the levels of proinflammatory monocytes. This could contribute to the decrease in atherosclerosis in GSD Ia.

We also found that fasted L-G6pc<sup>−/−</sup> mice exhibit prolonged bleeding time in the tail vein bleeding assay, replicating the enhanced bleeding tendency in GSD Ia patients with poor glycemic control [16–18]. Various mechanisms have been proposed for this observation, including decreases in vWF [19], disturbed platelet aggregation [16,18], and increased blood pressure [48]. Because GSD Ia is a rare disorder, studies typically include small numbers of patients (between 2 and 7 per study), and hence, the bleeding phenotype in GSD Ia has not been evaluated systematically. We found that some coagulation factors secreted by the liver, one of the main organs affected in GSD Ia, were increased in L-G6pc<sup>−/−</sup> mice upon fasting, as were FVIII and vWF; however, these increases would rather have led to increased coagulation and thus cannot explain the bleeding phenotype in GSD Ia. Strikingly, we observed that only in the fasted condition, L-G6pc<sup>−/−</sup> mice showed disturbed platelet aggregation. This was reflected by ~50% platelet disaggregation in response to ADP after maximum aggregation had been reached. This indicates that the secondary wave of platelet aggregation, which is dependent on the release of ADP and ATP stored in the dense granules of platelets [73,74], is absent in hepatocyte-specific G6pc1 deficiency. Therefore, the platelet activation process and recruitment of platelets cannot be amplified and a solid platelet plug cannot be formed [73–76]. This is commonly observed in patients with dense granule storage pool disease [77], which is characterized by an almost complete absence of dense granule ADP and ATP levels in the platelet dense granules due to hypoglycemia [18]. Continuous gastric drip feeding to maintain normoglycemia corrected ADP and ATP levels along with the disturbed platelet aggregation phenotype [18]. Together with our results in mice with hepatocyte-specific G6pc1 deficiency, these findings indicate that disturbed platelet aggregation in GSD Ia is the consequence of low levels of ATP and ADP in the platelet dense granules due to hypoglycemia. In addition, we cannot exclude that the decrease in myeloid cells in L-G6pc<sup>−/−</sup> mice may have led to a decrease in absolute numbers of monocyte- and neutrophil-platelet aggregates, which could contribute to increased bleeding in fasted L-G6pc<sup>−/−</sup> mice compared to controls.
Several studies have shown that glucose levels affect platelet aggregation. Platelet deficiency of GLUT 1 and GLUT 3, which mediate glucose uptake, decreases platelet activation in response to protease-activated receptor 4 peptide (PAR4) and prolongs bleeding time in mice [80,81]. These observations support our finding that bleeding time is increased in fasting-induced hypoglycemia in L-G6pc−/− mice. However, in contrast to findings in GSD Ia [16–18], acute hypoglycemia during an insulin stress test in humans increases platelet aggregation in response to ADP without affecting platelet ATP and ADP content [82]. The exact mechanism for this finding is unclear. Furthermore, acute insulin-induced hypoglycemia has been demonstrated to increase vWF levels in humans [83,84], likely the consequence of the hypoglycemia-induced increase in corticosterone levels [51,52] or endothelial dysfunction [84,85], and enhancing platelet aggregation. In sum, several mechanisms affecting platelet aggregation or disaggregation, including the one identified in GSD Ia, are regulated by blood glucose levels.

A limitation of our study is the use of adult, hepatocyte-specific G6pc1 deficient mice. Whole body G6pc1−/− mice require daily glucose injections to survive, they rarely live longer than 3 months, and cannot be used to investigate the effects of G6pc1 deficiency during fasting [11,86,87]. Although kidney-specific and intestinal-specific G6pc1 deficient mice do not become hypoglycemic upon fasting [88–90], we cannot exclude that in GSD Ia patients, loss of G6pc activity in kidney and intestine contributes to the bleeding phenotype under conditions of poor glycemic control.

5. CONCLUSION

We have shown that hepatocyte-specific G6pc1 deficiency increases plasma corticosterone levels upon fasting, which decreases Ly6Ch+ monocytes in the blood. Although direct effects of poor glycemic control on cortisol or leukocyte levels have not been evaluated in GSD Ia patients, this would be of interest, especially because increased plasma cortisol may contribute to elevated VLDL-TG under conditions of poor glycemic control in GSD Ia. In addition, we found that hepatocyte-specific G6pc1 deficiency disturbs platelet aggregation during fasting-induced hypoglycemia, accounting for the bleeding phenotype in GSD Ia. Together, these results highlight the clinical necessity of good glycemic control in GSD Ia.

CREDIT AUTHOR STATEMENT

Anouk M. La Rose: Conceptualization, Methodology, Investigation, Writing — Original Draft preparation. Venetia Bazioti, Joanne A. Hoogerland, Arthur F. Svendsen, Anouk G. Groenen, Martijn van Faassen, Martijn G.S. Rutten, Niels J. Kloosterhuis, Bertien Dethmers-Ausema, J. Hendrik Nijland: Investigation. G. Mitthieu, F. Rajas: Resources, Writing — Review & Editing. M.V. Lukens, F. Kuipers, O. Soehnlein, M.H. Oosterveer: Conceptualization, Writing — Review & Editing. M. Westerterp: Conceptualization, Methodology, Investigation, Writing — Review & Editing, Supervision, Funding Acquisition.

ACKNOWLEDGMENTS

The authors thank Vincent Bloks for his help on the hepatic coagulation factor analysis. M.H. Oosterveer and M. Westerterp are both supported by VIDI grants (917.17.373 and 917.15.350, respectively) from the Netherlands Organization of Scientific Research, and Rosalind Franklin Fellowships from the University of Groningen.

CONFLICT OF INTEREST

None declared.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2021.101265.

REFERENCES

[1] Chou, J.Y., Jun, H.S., Mansfield, B.C., 2015. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase/glucose-6-phosphate transporter complexes. Journal of Inherited Metabolic Disease 38:511–519.
[2] Lei, K.J., Shelly, L.L., Pan, C.J., Sidbury, J.B., Chou, J.Y., 1993. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science 262:580–583.
[3] Lei, K.J., Chen, Y.T., Chen, H., Wong, L.J.C., Liu, J.L., McConkie-Rosell, A., et al., 1995. Genetic basis of glycogen storage disease type 1a: prevalent mutations at the glucose-6-phosphatase locus. The American Journal of Human Genetics 57:766–771.
[4] Chevalier-Porst, F., Bozon, D., Bonardot, A.M., Bruni, N., Miltheux, G., Mathieu, M., et al., 1996. Mutation analysis in 24 French patients with glycogen storage disease type la. Journal of Medical Genetics 33:358–360.
[5] Chou, J.Y., Kim, G.-Y., Cho, J.-H., 2017. Recent development and gene therapy for glycogen storage disease type la. Liver Research 1:174–180.
[6] Dambiska, M., Labrador, E.B., Kuo, C.L., Weinstein, D.A., 2017. Prevention of complications in glycogen storage disease type la with optimization of metabolic control. Pediatric Diabetes 18:327–331.
[7] Rakie, J.P., Visser, G., Labrune, P., Leonard, J.V., Ulrich, K., Smit, G.P.A., et al., 2002. Guidelines for management of glycogen storage disease type I - European study on glycogen storage disease type I (ESGSD I). European Journal of Pediatrics 161:S112–S119.
[8] Carvalho, P.M.S., Silva, N.J.M.M., Dias, P.G.D., Porto, J.F.C., Santos, L.C., Costa, J.M.N., 2013. Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases. Journal of Diabetes and Metabolic Disorders 12:25.
[9] Rakie, J.P., Visser, G., Labrune, P., Leonard, J.V., Ulrich, K., Smit, G.P., 2002. Glycogen storage disease type I : diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I ). European Journal of Pediatrics 161:S20–S34.
[10] Hoogerland, J.A., Peeks, F., Hijmans, B., Wolters, J.C., Kooijman, S., Bos, T., et al., 2021. Impaired VLDL catabolism links hypoglycemia to hyperglycemia in GSDIa. Journal of Inherited Metabolic Disease [Epub ahead of print].
[11] Lei, K., Chen, H., Pan, C., Ward, J.M., Mosingin, B., Lee, E.J., et al., 1996. Glucose-6-phosphatase dependent substrate transport in the glycogen storage disease type 1a mouse. Nature Genetics 13:203–209.
[12] Lei, Y., Hoogerland, J.A., Bloks, V.W., Bos, T., Bleeker, A., Wolters, H., et al., 2020. Hepatic carbohydrate response element binding protein activation limits nonalcoholic fatty liver disease development in a mouse model for glycogen storage disease type 1a. Hepatology 72:1638–1653.
[13] Wang, D., Fiske, L., Carreras, C., Weinstein, D., 2011. Natural history of hepatocellular adenoma formation in glycogen storage disease type I. Journal of Pediatrics 159:442–446.
[14] Beegle, R.D., Brown, L.M., Weinstein, D.A., 2015. Regression of hepatocellular adenomas with strict dietary therapy in patients with glycogen storage disease type I. JIMD Report 18:23–32.
[15] Ubels, F., Rakie, J., Smit, P., Smit, A., Slaets, J., 2002. Is glycogen storage disease 1a associated with atherosclerosis? European Journal of Pediatrics 161:S62–S64.
[16] Czapek, E.E., Deykin, D., Salzman, E.W., 1973. Platelet dysfunction in glycogen storage disease type I. Blood 41:235–247.

[17] Corby, D.G., Putsam, C.W., Greene, H.L., 1974. Impaired platelet function in glucose-6-phosphatase deficiency. Journal of Pediatrics 85:71–76.

[18] Hutton, R.A., Macnab, A.J., Rivers, R.P.A., 1976. Defect of platelet function associated with chronic hypoglycaemia. Archives of Disease in Childhood 51:49–55.

[19] Mühlhausen, C., Schneppenheim, R., Budde, U., Merkel, M., Muschol, N., Ullrich, K., et al., 2005. Decreased plasma concentration of von Willebrand factor antigen (WF:Ag) in patients with glycogen storage disease type Ia. Journal of Inherited Metabolic Disease 28:945–950.

[20] Bandsma, R.H.J., Rake, J.P., Visser, G., Reese, R.A., Hellerstein, M.K., Van Duyvenvoorde, W., et al., 2002. Increased ipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type Ia. Journal of Pediatrics 140:256–260.

[21] Peeks, F., Steunenberg, T.A.H., de Boer, F., Rubio-gozalbo, M.E., Williams, M., Nagareddy, P.R., Murphy, A.J., Stirzaker, R.A., Hu, Y., Yu, S., Miller, R.G., et al., 2019. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 178:1102–1114 e17.

[22] Nagareddy, P.R., Murphy, A.J., Stirzaker, R.A., Hu, Y., Yu, S., Miller, R.G., et al., 2013. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metabolism 17:695–708.

[23] Jordan, S., Tung, N., Casanova-Acebes, M., Chang, C., Cantoni, C., Zhang, D., et al., 2019. Dietary intake regulates the circulating inflammatory monocyte pool. Cell 178:1102–1114 e17.

[24] Mansour, A., Roussel, M., Gaussem, P., Nédélec-Gac, F., Pontis, A., Flècher, E., et al., 2020. Matrix derivatization combined with LC-MS/MS results in ultrasensitive quantification of protein digestion products. Analytical Chemistry 92:9072–9080.

[25] Kraakman, M.J., Lee, M.K.S., Al-Sharea, A., Dragoljevic, D., Barrett, T.J., Celi, A., Pellegrini, G., Lorenzet, R., De Blasi, A., Ready, N., Furie, B.C., et al., 2019. Candidate reference measurement procedure for the quantification of glucose-6-phosphate in blood. Glycobiology 29:1321–1335.

[26] Celi, A., Pellegrini, G., Lorenzet, R., De Blasi, A., Ready, N., Furie, B.C., et al., 2010. Selective mobilization of cytotoxic T lymphocytes by epinephrine. The Journal of Immunology 184:503–511.

[27] Shum, K., Inouye, K., Chan, O., Mathoo, J., Blininski, D., Matthews, S.G., et al., 2001. Effects of antecedent hypoglycemia, hyperinsulinemia, and excess corticosterone on hypoglycemic counterregulation. American Journal of Physiology. Endocrinology and Metabolism 281:455–465.

[28] Dhabhar, F.S., Miller, A.H., McEwen, B.S., Spencer, R.L., 1995. Effects of stress on immune cell distribution: dynamics and hormonal mechanisms. The Journal of Immunology 154:5511–5527.

[29] Thompson, J., van Furth, R., 1973. The effect of glucocorticosteroids on the proliferation and kinetics of monocytes and monocytes of the bone marrow. Journal of Experimental Medicine 137:10–21.

[30] Wurtman, R.J., Axelrod, J., 1965. Adrenalin synthesis: control by the pituitary gland and adrenal glucocorticoids. Science 150:1464–1465.

[31] Dimitrov, S., Lange, T., Born, J., 2010. Selective mobilization of cytotoxic T lymphocytes by epinephrine. The Journal of Immunology 184:503–511.

[32] Serbina, N.V., Pamer, E.G., 2006. Monocyte emigration from bone marrow to the inflammatory site is delayed in mice with elevated chemokines and in atherosclerotic plaques. Journal of Clinical Investigation 117:1469–1473.

[33] Yetman, R.J., Andrew-Casal, M., Hermida, R.C., Dominguez, B.W., Portman, R.J., Northrup, H., et al., 2002. Circadian pattern of blood pressure, heart rate, and double product in liver glycogen storage disease. Chronobiology International 19:765–783.

[34] Kujovich, J.L., 2015. Coagulopathy in liver disease: a balancing act. Hematology American Society Hematology Education Programs 243–9.

[35] Dal Bo Zanon, R., Fornasier, L., Boscaro, M., Cappellato, G., Fabris, F., Girolami, A., 1982. Increased factor VIII associated activities in Cushing syndrome: a probable hypercoagulable state. Thrombosis & Haemostasis 47:116–117.

[36] Girolami, A., 1982. Increased factor VIII associated activities in Cushing syndrome: a probable hypercoagulable state. Thrombosis & Haemostasis 47:116–117.
